These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 11025609

  • 1. Use of molecular techniques to confirm true re-emergence of the original clone and to track minimal residual disease in a case of late extramedullary relapse of childhood acute lymphoblastic leukemia.
    Valetto A, Anselmi G, Scuderi F, Lanciotti M, Chiesa V, Dini G.
    Haematologica; 2000 Oct; 85(10):1102-3. PubMed ID: 11025609
    [No Abstract] [Full Text] [Related]

  • 2. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
    Aricò M, Germano G, del Giudice L, Ziino O, Locatelli F, Basso G.
    Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
    [No Abstract] [Full Text] [Related]

  • 3. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 4. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
    Foroni L, Harrison CJ, Hoffbrand AV, Potter MN.
    Br J Haematol; 1999 Apr 20; 105(1):7-24. PubMed ID: 10366253
    [No Abstract] [Full Text] [Related]

  • 5. Early detection of central nervous system relapse by polymerase chain reaction in children with B-precursor acute lymphoblastic leukemia.
    de Haas V, Vet RJ, Verhagen OJ, Kroes W, van den Berg H, van der Schoot CE.
    Ann Hematol; 2002 Jan 20; 81(1):59-61. PubMed ID: 11807640
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B.
    Cytometry B Clin Cytom; 2005 Nov 20; 68(1):18-24. PubMed ID: 16184615
    [Abstract] [Full Text] [Related]

  • 7. Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Ph-negative acute lymphoblastic leukaemia?
    Giebel S, Krawczyk-Kulis M, Kyrcz-Krzemien S, Haus O, Jagoda K, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Chrobok A, Stella-Holowiecka B, Kielbinski M, Holowiecki J.
    Br J Haematol; 2009 Mar 20; 144(6):970-2. PubMed ID: 19120362
    [No Abstract] [Full Text] [Related]

  • 8. Clonal stability of initial leukemia in a child with central nervous system relapse 7.4 years after bone marrow relapse of common acute lymphoblastic leukemic.
    Eckert C, Einsiedel HG, Hartmann R, von Stackelberg A, Völpel S, Guggemos A, Hanzsch N, Kawan L, Seeger K, Henze G.
    Haematologica; 2004 Jul 20; 89(7):ECR23. PubMed ID: 15257960
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre.
    Motwani J, Jesson J, Sturch E, Jones S, Eyre L, Short P, Davies P, Williams MD, Darbyshire PJ, Hill FG, Lawson S.
    Br J Haematol; 2009 Jan 20; 144(1):133-5. PubMed ID: 19016737
    [No Abstract] [Full Text] [Related]

  • 10. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia.
    Specchia G, Liso A, Pannunzio A, Albano F, Mestice A, Pastore D, Liso V.
    Haematologica; 2004 Oct 20; 89(10):1271-3. PubMed ID: 15477219
    [Abstract] [Full Text] [Related]

  • 11. Monitoring minimal residual disease in pediatric hematologic malignancies.
    Campana D.
    Clin Adv Hematol Oncol; 2007 Nov 20; 5(11):876-7, 915. PubMed ID: 18185484
    [No Abstract] [Full Text] [Related]

  • 12. [Minimal residual disease in childhood acute leukemias].
    Pawińska K, Balwierz W, Baran J.
    Przegl Lek; 2006 Nov 20; 63(1):41-3. PubMed ID: 16892899
    [Abstract] [Full Text] [Related]

  • 13. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ.
    Best Pract Res Clin Haematol; 2002 Mar 20; 15(1):37-57. PubMed ID: 11987915
    [Abstract] [Full Text] [Related]

  • 14. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C, Dini G, Locatelli F, Miniero R, Tamaro P.
    Haematologica; 2000 Nov 20; 85(11 Suppl):47-53. PubMed ID: 11268324
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Acute lymphoblastic leukemia followed by a clonally-unrelated EBV-positive non-Hodgkin lymphoma and a clonally-related myelomonocytic leukemia cutis.
    Szczepański T, de Vaan GA, Beishuizen A, Bogman J, Jansen MW, van Wering ER, van Dongen JJ.
    Pediatr Blood Cancer; 2004 Apr 20; 42(4):343-9. PubMed ID: 14966831
    [Abstract] [Full Text] [Related]

  • 17. Eliminating a gold standard in childhood acute lymphoblastic leukemia?
    Raetz EA, Carroll WL.
    Pediatr Blood Cancer; 2006 Sep 20; 47(3):242-4. PubMed ID: 16421903
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 19. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 20; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 20. Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia.
    Mehta PA, Davies SM.
    Pediatr Blood Cancer; 2007 Jan 20; 48(1):1-2. PubMed ID: 16642487
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.